Biothera to Present Cancer Immunotherapy Research at BIO International Convention
Posted on: Monday, 7 May 2007, 15:01 CDT
Biothera, a biotechnology company developing pharmaceuticals that prime the innate immune system and enhance drug efficacy, will present its clinical research at the BIO International Convention in Boston on May 6-9.
Steven J. Karel, Biothera's chief of technology operations, will discuss the company's novel technology and its applications in the areas of oncology, anti-infectives and hematopoiesis.
"Our technology has the potential to dramatically enhance both existing and developmental drug treatments for most major types of cancer," said Daniel K. Conners, Biothera founder and chairman. "Our lead compound, Imprime PGG™, is a biological response modifier that enhances specific innate immune cell responses."
Biothera has two active Investigational New Drug (IND) filings with the U.S. Food and Drug Administration. The company has completed:
Two Phase I clinical trials with in support of its cancer IND for the use of Imprime PGG in combination with anti-cancer monoclonal antibodies.
A Phase I/II trial with Imprime PGG in combination with a hematopoietic growth factor.
Biothera plans to initiate multiple Phase Ib and Phase II studies with Imprime PGG in combination with anti-cancer monoclonal antibodies.
Event Details
Meeting: Biotechnology Industry Organization (BIO) International Convention
Presenter: Steven J. Karel Biothera Chief of Technology Operations
Date/Time: Tuesday, May 8th at 2:15 pm
Location: Boston Convention & Exhibition Center BIO Business Forum Level 1 of BCEC at the North Lobby
Biothera will conduct individual meetings with corporate partner and licensing candidates during the convention. To schedule a meeting, contact Robert J. Brown, senior vice president, Corporate Development, at 651-675-0300 or at rbrown@biotherapharma.com.
About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals that engage the innate immune system to fight cancer. Other applications include hematopoietic (white blood cell) recovery and infectious disease. Website: www.biotherapharma.com.
Source: Business Wire
Related Articles
- Drug-Device Combination Market Worth US$18.54 Billion by 2014
- Biothera to Present Imprime PGG(R) Clinical Trial Results at the International Society for Biological Therapy of Cancer
- Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
- Biothera's Imprime PGG Increases Efficacy of Erbitux Against Non-Small Cell Lung Cancer, Study Finds
- Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
- Biothera's Imprime PGG(TM) Enhanced Effectiveness of Avastin(R) in Cancer Study
- Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device Combination Product - ChronoDose(TM)
- Community Oncology Alliance Refutes NBC Nightly News Story 'Cancer Docs Profit From Chemotherapy Drugs'
- Biothera Completes Phase I Clinical Trial for Imprime PGG
- U-Turn Allows Cancer Patients to Get New Drug
 |
 |
User Comments (0)
RSS Feeds